The European Leadership Summit on Chronic Care

3-4 December, 2007, Amsterdam, The Netherlands
Organised under the high patronage of the European Commission, the event will convene senior executives from key organisations advancing chronic care in Europe including providers, payers, suppliers, customers, policy-makers and health officials.

The European Leadership Summit on Chronic Care is the forum where government and industry leaders share successful initiatives and best practices. So far, the agenda includes case studies from 12 different countries.

Through the support of our partner organizations, we are creating a truly international event, reaching key health leaders in over 40 countries. An international delegation will enjoy this two-day networking opportunity, featuring visionary keynote addresses, controversial debates, implementation case studies, tutorials and informal roundtable discussions.

Four focused summits will give attendees a unique opportunity to discuss pertinent issues in depth and determine actionable plans with their colleagues:

  • IT Infrastructures, Electronic Health Records and Chronic Care
  • Aligning Financial Incentives and Restructuring Care
  • Telehealth and Remote Monitoring
  • Empowering Patients and Supporting Self-Care

Two best practice seminars will also explore disease specific initiatives for:

  • Diabetes
  • Cardiovascular and Lung Diseases

For further information and registration, please visit:
http://www.worldcongress.com/events/HL07080/

Most Popular Now

AstraZeneca takes next steps towards broad and equ…

AstraZeneca has taken the next steps in its commitment to broad and equitable global access to the University of Oxford’s COVID-19 vaccine, following landmark agreements ...

Johnson & Johnson announces acceleration of it…

Johnson & Johnson (NYSE: JNJ) (the Company) today announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2...

Low-cost dexamethasone reduces death by up to one …

In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for C...

Sanofi invests to make France its world class cent…

Sanofi detailed plans on how the Company will make significant investments in France to increase its vaccines research and production capacities, and contribute in respon...

Calquence showed promising clinical improvement in…

Results published in Science Immunology showed that Calquence (acalabrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor, reduced markers of inflammation and improved cl...

Super-potent human antibodies protect against COVI…

A team led by Scripps Research has discovered antibodies in the blood of recovered COVID-19 patients that provide powerful protection against SARS-CoV-2, the coronavirus ...

New consortium EUbOPEN will provide tools to unloc…

Almost twenty years after deciphering the human genome, our understanding of human disease is still far from complete. One of the most powerful and versatile tools to bet...

AstraZeneca to supply Europe with up to 400 millio…

AstraZeneca has reached an agreement with Europe's Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 milli...

Up to 45 percent of SARS-CoV-2 infections may be a…

An extraordinary percentage of people infected by the virus behind the ongoing deadly COVID-19 pandemic never show symptoms of the disease, according to the results of a ...

Researchers identify potent antibody cocktail to t…

Researchers at the University of Maryland School of Medicine (UMSOM) evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail...

Gilead announces results from Phase 3 Trial of rem…

Gilead Sciences, Inc. (Nasdaq: GILD) announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This open-label st...

Mayo finds convalescent plasma safe for diverse pa…

Mayo Clinic researchers and collaborators have found investigational convalescent plasma to be safe following transfusion in a diverse group of 20,000 patients. The findi...